Loading…
Loading…
Merck & Co. NYSE: MRK and Moderna NASDAQ: MRNA just cleared a bar no cancer vaccine had cleared before. Their personalized melanoma vaccine succeeded in a Phase 3 trial.
Moderna Inc. (NASDAQ:MRNA) shares are trading lower Tuesday after William Blair downgraded the stock to Market Perform from Outperform on Monday, citing valuation concerns.
Moderna CEO Stéphane Bancel says the biotech's competitive edge stems from its mRNA platform, likening it to software in Big Tech.
Wall Street analysts are reshuffling their bets across chips, crypto, energy, and beyond as the Fed prepares to deliver its next rate verdict. Find out which stocks got surprise upgrades, which took hits despite soaring triple-digit gains, and why one natural gas deal is rewriting the Appalachian energy map.
FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
Leaked data from Moderna and Merck's highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. Normally results of such pivotal drug studies are binary, with doctors, patients and investors all learning whether a novel medicine will make a meaningful difference in people's lives and forming the same conclusion.
Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker's experimental cancer treatment.